Suppr超能文献

中重度特应性皮炎成人患者疾病控制不足的程度和后果。

Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis.

机构信息

Sanofi, New Jersey, USA.

Adelphi Real World, Cheshire, UK.

出版信息

J Dermatol. 2018 Feb;45(2):150-157. doi: 10.1111/1346-8138.14116. Epub 2017 Nov 13.

Abstract

Since control of atopic dermatitis (AD) remains challenging but has not been adequately characterized, the objective of this study was to characterize disease control among patients with a history of moderate to severe AD. Data were from the 2014 Adelphi US AD Disease Specific Programme, a cross-sectional survey of physicians (n = 202) and their patients with history of moderate to severe AD (n = 1064, 54% female, 75% white, mean age 40 years). Inadequately controlled AD as rated by the physician was defined as currently flaring; deteriorating/changeable AD; or physician dissatisfaction with current control. The overall inadequate control rate was 58.7% (n = 625), which increased with current AD severity and was observed in 53.4% and 83.4% of patients receiving immunosuppressants and systemic corticosteroids, respectively. Relative to controls, inadequately controlled patients had poorer disease-specific quality of life, higher level of work impairment, greater itch and sleep interference with daily living (all P < 0.05). Multivariate analysis showed factors significantly associated with inadequate control (all P < 0.05), including Hispanic race, symptoms on the head/neck or lower limbs, itch and sleep interference with daily living. A limitation of the study was reliance on accuracy of reporting, potential selection bias and cross-sectional study design. In summary, there was a high rate and substantial impact of physician-rated inadequately controlled disease among patients with a history of moderate to severe AD, suggesting the need for more effective therapies.

摘要

由于特应性皮炎(AD)的控制仍然具有挑战性,但尚未得到充分描述,本研究的目的是描述有中度至重度 AD 病史患者的疾病控制情况。数据来自于 2014 年 Adelphi 美国 AD 疾病专项计划,这是一项横断面调查,涉及医生(n=202)及其有中度至重度 AD 病史的患者(n=1064,54%为女性,75%为白人,平均年龄 40 岁)。医生评定的 AD 控制不佳定义为当前病情恶化;病情恶化/变化;或医生对当前控制不满意。总体控制不佳率为 58.7%(n=625),随着当前 AD 严重程度的增加而增加,分别在接受免疫抑制剂和全身皮质类固醇治疗的患者中观察到 53.4%和 83.4%。与对照组相比,控制不佳的患者疾病特异性生活质量更差,工作受损程度更高,瘙痒和睡眠对日常生活的干扰更大(均 P<0.05)。多变量分析显示,与控制不佳显著相关的因素(均 P<0.05)包括西班牙裔种族、头部/颈部或下肢的症状、瘙痒和睡眠对日常生活的干扰。该研究的局限性在于依赖报告的准确性、潜在的选择偏倚和横断面研究设计。总之,有中度至重度 AD 病史的患者中,医生评定的疾病控制不佳率很高,且影响很大,表明需要更有效的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b5c/5813133/143a9f506c27/JDE-45-150-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验